Literature DB >> 22254213

Pathogenesis of aortic sclerosis: association with low BMI, tissue nitric oxide resistance, but not systemic inflammatory activation.

Aaron L Sverdlov1, Doan Tm Ngo, John D Horowitz.   

Abstract

Aortic sclerosis (ASc) represents the earliest stage of development of aortic valve thickening, and may eventually progress to aortic valve stenosis (AS). ASc is associated with intra-valvular inflammatory activation, and potentially with attenuation of the anti-inflammatory effect of nitric oxide (NO). We have shown that ASc occurs less frequently in obese individuals, in whom systemic inflammatory activity is generally increased. We explored these relationships further by stratifying a population of 253 ageing individuals according to BMI. Increasing BMI was associated with increased hs-CRP concentrations (r=0.43; p<0.001). However, presence/absence of ASc did not significantly modify this relationship. Furthermore, increasing BMI was independent of tissue responsiveness to NO, as measured via inhibition of platelet aggregation by the NO donor sodium nitroprusside. Therefore the association of low BMI with increased risk of ASc appears to interact neither with systemic inflammatory activation in such individuals, nor with any "paradoxical" occurrence of NO resistance.

Entities:  

Keywords:  Aortic valve sclerosis; BMI; inflammation; nitric oxide

Year:  2011        PMID: 22254213      PMCID: PMC3257151     

Source DB:  PubMed          Journal:  Am J Cardiovasc Dis        ISSN: 2160-200X


  35 in total

1.  Determinants of progression of aortic stenosis in patients aged > or =40 years.

Authors:  Nattawut Wongpraparut; Sirin Apiyasawat; Guillermo Crespo; Kambis Yazdani; Larry E Jacobs; Morris N Kotler
Journal:  Am J Cardiol       Date:  2002-02-01       Impact factor: 2.778

2.  Association of aortic stenosis with platelet hyperaggregability and impaired responsiveness to nitric oxide.

Authors:  Yuliy Y Chirkov; Andrew S Holmes; Scott R Willoughby; Simon Stewart; John D Horowitz
Journal:  Am J Cardiol       Date:  2002-09-01       Impact factor: 2.778

3.  The risk of the development of aortic stenosis in patients with "benign" aortic valve thickening.

Authors:  John E Cosmi; Smadar Kort; Paul A Tunick; Barry P Rosenzweig; Robin S Freedberg; Edward S Katz; Robert M Applebaum; Itzhak Kronzon
Journal:  Arch Intern Med       Date:  2002-11-11

4.  Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM.

Authors:  G Anfossi; E M Mularoni; S Burzacca; M C Ponziani; P Massucco; L Mattiello; F Cavalot; M Trovati
Journal:  Diabetes Care       Date:  1998-01       Impact factor: 19.112

5.  Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study.

Authors:  Gian M Novaro; Ronit Katz; Ronnier J Aviles; John S Gottdiener; Mary Cushman; Bruce M Psaty; Catherine M Otto; Brian P Griffin
Journal:  J Am Coll Cardiol       Date:  2007-10-29       Impact factor: 24.094

Review 6.  The body mass index paradox and an obesity, inflammation, and atherosclerosis syndrome in chronic kidney disease.

Authors:  Srinivasan Beddhu
Journal:  Semin Dial       Date:  2004 May-Jun       Impact factor: 3.455

7.  Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis.

Authors:  K D O'Brien; D D Reichenbach; S M Marcovina; J Kuusisto; C E Alpers; C M Otto
Journal:  Arterioscler Thromb Vasc Biol       Date:  1996-04       Impact factor: 8.311

8.  Factors associated with calcific aortic valve degeneration in the elderly.

Authors:  M Lindroos; M Kupari; J Valvanne; T Strandberg; J Heikkilä; R Tilvis
Journal:  Eur Heart J       Date:  1994-07       Impact factor: 29.983

9.  Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial.

Authors:  Kwan Leung Chan; Koon Teo; Jean G Dumesnil; Andy Ni; James Tam
Journal:  Circulation       Date:  2010-01-04       Impact factor: 29.690

Review 10.  Calcific aortic stenosis: lessons learned from experimental and clinical studies.

Authors:  Nalini M Rajamannan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-11-20       Impact factor: 8.311

View more
  3 in total

1.  Relationship of PON1 192 and 55 gene polymorphisms to calcific valvular aortic stenosis.

Authors:  Luis M Moura; Susana Faria; Miguel Brito; Fausto J Pinto; Steen D Kristensen; Isabel M Barros; Nalini Rajamannan; Francisco Rocha-Gonçalves
Journal:  Am J Cardiovasc Dis       Date:  2012-05-15

2.  Aortic valve sclerosis is a high predictive marker of systemic endothelial dysfunction in hypertensive patients.

Authors:  T Erdoğan; M Cetin; S A Kocaman; M E Durakoğlugil; E Ergül; A Canga
Journal:  Herz       Date:  2013-02-13       Impact factor: 1.443

Review 3.  Impairment of Anti-Aggregatory Responses to Nitric Oxide and Prostacyclin: Mechanisms and Clinical Implications in Cardiovascular Disease.

Authors:  Yuliy Y Chirkov; Thanh H Nguyen; John D Horowitz
Journal:  Int J Mol Sci       Date:  2022-01-18       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.